Business
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 S...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting\n\n\n\n\n MDNA113 is a novel IL-13Rα2\n \n\n tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2\n \n\n\n SK\n \n\n\n ), engineered to precisely deliver clinically validated anti-PD1 and IL-2\n \n\n\n SK\n \n\n\n to the tumor microenvironment (TME)\n \n\n\n\n IL-13Rα2 is overexpressed by some of the most “immunologically cold” tumors with high unmet needs in pancreatic, liver, brain, breast, colon and prostate cancer that annually affect over 2 million patients worldwide\n \n\n\n\n MDNA113’s tumor targeting together with conditional activation provides a highly differentiated and potentially superior approach to current anti-PD-1-IL-2 bispecifics in development\n \n\n\n TORONTO and HOUSTON, April 30, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today presents new pre-clinical data from MDNA113, its first candidate from the BiSKIT (Bifunctional SuperKine ImmunoTherapies) platform, at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois.\n \n\n “Our MDNA113 program continues to generate encouraging pre-clinical data that underscores its potential as a first-in-class immunotherapy for immunologically cold tumors,” said Fahar Merchant, Ph.D., President and CEO of Medicenna. “MDNA113 is uniquely differentiated against competing anti-PD-1-IL-2 therapies, with an optimized safety and efficacy profile that leverages its clinically validated pharmacology and novel IL-13 targeting approach. Not only are we observing compelling anti-tumor activity in IL-13Rα2 positive tumors but also signs of enhanced memory that may support durable responses. Commercial interest for bi-specific anti-PD-1 therapies is gaining momentum, with several recent transactions validating this emerging class of immunotherapies with the potential to offer new hope to millions of cancer patients worldwide.”\n \n\n MDNA113...